Want to see IN:COHANCE full AI Analyst Report?

Suven Pharmaceuticals Ltd. (COHANCE) Price & Analysis

3 Followers

COHANCE Stock Chart & Stats

₹891.10

₹6.60(0.60%)

At close: Jan 08 4:00 PM EST

₹891.10

₹6.60(0.60%)

Day’s Range― - ―

52-Week Range₹267.85 - ₹917.50

Previous CloseN/A

VolumeN/A

Average Volume (3M)240.46K

Market Cap

₹175.63B

Enterprise Value₹172.65K

Total Cash (Recent Filing)₹4.59B

Total Debt (Recent Filing)₹2.08B

Price to Earnings (P/E)107.4

Beta0.93

Next Earnings

Nov 11, 2026

EPS Estimate

1.14

Next Dividend Ex-DateN/A

Dividend Yield1.68%

Share Statistics

EPS (TTM)4.22

Shares Outstanding382,597,320

10 Day Avg. Volume83,464

30 Day Avg. Volume240,462

Financial Highlights & Ratios

PEG Ratio-1.17

Price to Book (P/B)2.95

Price to Sales (P/S)5.08

P/FCF Ratio85.28

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹350.00

Price Target Upside-60.72% Downside

Rating ConsensusModerate Sell

Number of Analyst Covering1

EPS Forecast (FY)5.96

Revenue Forecast (FY)₹23.19B

Bulls Say, Bears Say

Bulls Say

Strong Revenue GrowthRapid FY2026 revenue growth indicates stronger customer activity and expanding commercial demand for the company’s pharmaceutical development and manufacturing services. If sustained, this larger revenue base can support scale benefits, broader customer programs, and future earnings recovery.

Conservatively Financed Balance SheetVery low leverage gives Suven financial flexibility to fund capacity, development programs, and working-capital needs without heavy dependence on borrowing. The larger equity and asset base also improves resilience if pharmaceutical demand or customer project timing becomes less predictable.

Improved Operating Cash FlowImproved operating cash flow provides an important foundation for funding the business internally, even though overall cash conversion weakened. Stronger cash generation from operations can support ongoing customer programs and reduce reliance on external financing over the medium term.

Bears Say

Sharp Margin CompressionThe steep decline in gross and net margins shows that higher sales are currently producing a much smaller profit contribution. Persistent margin pressure would weaken earnings quality, reduce reinvestment capacity, and make results more dependent on continued revenue growth rather than efficient execution.

Weak Free-Cash-Flow ConversionLow conversion of accounting profit into free cash flow limits the resources available for capacity expansion, debt reduction, and shareholder returns. The deterioration from stronger conversion in FY2022–FY2024 suggests working-capital or reinvestment demands may remain a material drag on financial quality.

Severe Earnings Per Share DeclineA sharp EPS contraction indicates that the substantial revenue increase has not translated into comparable per-share earnings growth. This weakens the near-term earnings base and signals that profitability, rather than demand alone, is the key challenge for sustained shareholder value creation.

Suven Pharmaceuticals Ltd. News

Cohance Lifesciences Completes USFDA Inspection at Shamshabad Plant

An update from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences Limited has reported the...

25d ago

Berhyanda affirms no new encumbrances on Cohance Lifesciences promoter shares for FY 2025-26

The latest update is out from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ). Berhyanda Limited, a promoter of Cohance...

3M ago

Cohance Lifesciences CFO and Whole-Time Director Himanshu Agarwal to Resign in September 2026

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an update. Cohance Lifesciences Limited has announced that Himanshu Agarwal,...

3M ago

Cohance Lifesciences Says Volume Surge in Shares Is Market-Driven

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has shared an update. Cohance Lifesciences has responded to a query from...

6M ago

Cohance Lifesciences Appoints Sisir K. Mishra as Company Secretary and Compliance Officer

Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) has provided an announcement. Cohance Lifesciences has appointed Sisir K. Mishra as...

6M ago

Cohance Lifesciences Grants 198,711 Stock Options Under ESOP 2023

An announcement from Suven Pharmaceuticals Ltd. ( ($IN:COHANCE) ) is now available. Cohance Lifesciences has approved the grant...

7M ago

COHANCE FAQ

What was Suven Pharmaceuticals Ltd.’s price range in the past 12 months?

Suven Pharmaceuticals Ltd. lowest stock price was ₹267.85 and its highest was ₹917.50 in the past 12 months.

What is Suven Pharmaceuticals Ltd.’s market cap?

Suven Pharmaceuticals Ltd.’s market cap is ₹175.63B.

When is Suven Pharmaceuticals Ltd.’s upcoming earnings report date?

Suven Pharmaceuticals Ltd.’s upcoming earnings report date is Nov 11, 2026 which is in 42 days.

How were Suven Pharmaceuticals Ltd.’s earnings last quarter?

Suven Pharmaceuticals Ltd. released its earnings results on Aug 05, 2026. The company reported -₹0.615 earnings per share for the quarter, missing the consensus estimate of -₹0.6 by -₹0.015.

Is Suven Pharmaceuticals Ltd. overvalued?

According to Wall Street analysts Suven Pharmaceuticals Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Suven Pharmaceuticals Ltd. pay dividends?

Suven Pharmaceuticals Ltd. pays a Notavailable dividend of ₹5 which represents an annual dividend yield of 1.68%. See more information on Suven Pharmaceuticals Ltd. dividends here

What is Suven Pharmaceuticals Ltd.’s EPS estimate?

Suven Pharmaceuticals Ltd.’s EPS estimate is 1.14.

How many shares outstanding does Suven Pharmaceuticals Ltd. have?

Suven Pharmaceuticals Ltd. has 382,597,320 shares outstanding.

What happened to Suven Pharmaceuticals Ltd.’s price movement after its last earnings report?

Suven Pharmaceuticals Ltd. reported an EPS of -₹0.615 in its last earnings report, missing expectations of -₹0.6. Following the earnings report the stock price went up 0.882%.

Which hedge fund is a major shareholder of Suven Pharmaceuticals Ltd.?

Currently, no hedge funds are holding shares in IN:COHANCE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Suven Pharmaceuticals Ltd.

Headquartered in Hyderabad, Cohance Lifesciences Limited operates as a pharmaceutical enterprise, with primary expertise in contract development and manufacturing (CDMO) services. Its business scope also includes the creation of active pharmaceutical ingredients (APIs) and diverse specialty chemicals. The company, previously known as Suven Pharmaceuticals Limited, underwent a corporate rebranding following its amalgamation with Cohance Lifesciences, a transition officially effective May 1, 2025.

Suven Pharmaceuticals Ltd. (COHANCE) Earnings & Revenues

Historic Earnings Reports

COHANCE Stock 12 Month Forecast

Average Price Target

₹350.00

▼(-60.72% Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"302":"₹302","903":"₹903","452.25":"₹452.3","602.5":"₹602.5","752.75":"₹752.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹350.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":350,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹350.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[302,452.25,602.5,752.75,903],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.75,451.3076923076923,442.86538461538464,434.4230769230769,425.9807692307692,417.53846153846155,409.09615384615387,400.6538461538462,392.21153846153845,383.7692307692308,375.3269230769231,366.88461538461536,358.44230769230774,{"y":350,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.75,451.3076923076923,442.86538461538464,434.4230769230769,425.9807692307692,417.53846153846155,409.09615384615387,400.6538461538462,392.21153846153845,383.7692307692308,375.3269230769231,366.88461538461536,358.44230769230774,{"y":350,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,459.75,451.3076923076923,442.86538461538464,434.4230769230769,425.9807692307692,417.53846153846155,409.09615384615387,400.6538461538462,392.21153846153845,383.7692307692308,375.3269230769231,366.88461538461536,358.44230769230774,{"y":350,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":902.15,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":870.1,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":753.2,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":553.25,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":523.5,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":371,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":303.7,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":311.55,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":482.95,"date":1777593600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":429.4,"date":1780272000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":451.3,"date":1782864000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":425.05,"date":1785542400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":459.75,"date":1788220800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >